Pharming Group (OTCMKTS:PHGUF) Shares Gap Up - Time to Buy?

Key Points

• Shares gapped up premarket from $1.51 to $1.6350 on Monday with light volume (1,082 shares); the stock sits near its moving averages ($1.60 50-day, $1.65 200-day) and has a market cap of about $1.10 billion.
• Quarterly results showed EPS of $0.01 and revenue beat of $106.5 million versus $89.72 million expected, but the company has thin profitability (net margin 0.71%, ROE 1.08%) and a high PE ratio of 163.66.
• Pharming is a Netherlands-based biopharmaceutical firm whose flagship product is RUCONEST for acute hereditary angioedema, and it maintains a diversified pipeline targeting rare and ultra-rare disorders.

Shares of Pharming Group NV (OTCMKTS:PHGUF - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $1.51, but opened at $1.6350. Pharming Group shares last traded at $1.6350, with a volume of 1,082 shares.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.59. The stock has a market cap of $1.10 billion, a PE ratio of 163.66 and a beta of 0.55. The company's 50-day moving average price is $1.60 and its two-hundred day moving average price is $1.65.

Pharming Group (OTCMKTS:PHGUF - Get Free Report) last announced its earnings results on Thursday, March 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $106.50 million during the quarter, compared to analyst estimates of $89.72 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.08%.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.